Literature DB >> 16140168

Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone.

Chi-Tso Chiu1, Tangeng Ma, Ing K Ho.   

Abstract

Repeated intermittent exposure to psychostimulants was found to produce behavioral sensitization. The present study was designed to establish a mouse model and by which to investigate whether opioidergic system plays a role in methamphetamine-induced behavioral sensitization. Mice injected with 2.5 mg/kg of methamphetamine once a day for 7 consecutive days showed behavioral sensitization after challenge with 0.3125 mg/kg of the drug on day 11, whereas mice injected with a lower daily dose (1.25 mg/kg) did not. Mice received daily injections with either 1.25 or 2.5 mg/kg of methamphetamine showed behavioral sensitization after challenge with 1.25 mg/kg of the drug on days 11, 21, and 28. To investigate the role of opioidergic system in the induction and expression of behavioral sensitization, long-acting but non-selective opioid antagonist naltrexone was administrated prior to the daily injections of and challenge with methamphetamine, respectively. Our results show that the expressions of behavioral sensitization were attenuated by pretreatment with 10 or 20 mg/kg of naltrexone either during the induction period or before methamphetamine challenge when they were tested on days 11 and 21. These results indicate that repeated injection with methamphetamine dose-dependently induced behavioral sensitization in mice, and suggest the involvement of opioid receptors in the induction and expression of methamphetamine-induced behavioral sensitization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140168      PMCID: PMC3138078          DOI: 10.1016/j.brainresbull.2005.05.028

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  58 in total

1.  Differential effects of morphine and cocaine on locomotor activity and sensitization in mu-opioid receptor knockout mice.

Authors:  Ji-Hoon Yoo; Eun-Mi Yang; Seok-Yong Lee; Horace H Loh; Ing K Ho; Choon-Gon Jang
Journal:  Neurosci Lett       Date:  2003-06-19       Impact factor: 3.046

2.  Distinct effects of methamphetamine and cocaine on preprodynorphin messenger RNA in rat striatal patch and matrix.

Authors:  David H Adams; Glen R Hanson; Kristen A Keefe
Journal:  J Neurochem       Date:  2003-01       Impact factor: 5.372

3.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

Review 4.  Amphetamine: effects on catecholamine systems and behavior.

Authors:  L S Seiden; K E Sabol; G A Ricaurte
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

5.  Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment.

Authors:  A Tempel; R S Zukin; E L Gardner
Journal:  Life Sci       Date:  1982 Sep 20-27       Impact factor: 5.037

6.  Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats.

Authors:  P E Paulson; D M Camp; T E Robinson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Increased responsiveness of ventral tegmental area dopamine neurons to glutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors.

Authors:  X F Zhang; X T Hu; F J White; M E Wolf
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

8.  Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli.

Authors:  M T Bardo; S L Bowling; R C Pierce
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine.

Authors:  R T Matthews; D C German
Journal:  Neuroscience       Date:  1984-03       Impact factor: 3.590

10.  Ultrastructural evidence of dopaminergic input to enkephalinergic neurons in rat neostriatum.

Authors:  Y Kubota; S Inagaki; S Kito; H Takagi; A D Smith
Journal:  Brain Res       Date:  1986-03-05       Impact factor: 3.252

View more
  26 in total

1.  Methamphetamine-induced expression of zif268 mRNA is prevented by haloperidol in mice lacking mu-opioid receptor.

Authors:  Lu-Tai Tien; Ing-Kang Ho; Tangeng Ma
Journal:  Neurotoxicology       Date:  2010-02-23       Impact factor: 4.294

2.  The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization.

Authors:  Steven M Graves; Amanda L Persons; Jennifer L Riddle; T Celeste Napier
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

3.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Authors:  Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2018-09-21       Impact factor: 4.492

Review 4.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

5.  The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-04       Impact factor: 3.584

6.  Opioid sensitivity in mice selectively bred to consume or not consume methamphetamine.

Authors:  Emily C Eastwood; Tamara J Phillips
Journal:  Addict Biol       Date:  2012-11-12       Impact factor: 4.280

7.  Pseudoginsenoside-F11 inhibits methamphetamine-induced behaviors by regulating dopaminergic and GABAergic neurons in the nucleus accumbens.

Authors:  Kequan Fu; Huiyang Lin; Yoshiaki Miyamoto; Chunfu Wu; Jingyu Yang; Kyosuke Uno; Atsumi Nitta
Journal:  Psychopharmacology (Berl)       Date:  2015-12-01       Impact factor: 4.530

8.  Neurotoxic effects of methamphetamine on rat hippocampus pyramidal neurons.

Authors:  N Hori; M T Kadota; M Watanabe; Y Ito; N Akaike; D O Carpenter
Journal:  Cell Mol Neurobiol       Date:  2010-03-16       Impact factor: 5.046

Review 9.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

Review 10.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.